Prevention

In addition give isosorbide mononitrate slow-release 50 mg po daily ^a

Why?

• It reduces rebleeding and mortality ^a

Isosorbide mononitrate added to sclerotherapy reduces rebleeding and death

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNT (95% CI)
cirrhosis and recent or current variceal bleed a	sclerotherapy and isosorbide mononitrate	sclerotherapy	rebleeding at 10 weeks	39%	72% (23% to 90%)	4 (2 to 10)
			death at 10 weeks	23%	77% (-1% to 95%)	6 (3 to 39)